Evidence map›Paper›PMID 41400063›Full record

SynthesisFuture oncology (London, England)2025

Shahd Hamran, Zaineh Alnoubani, Aly Mostafa Hassan, Amani A Al-Rajhi, Humam Emad Rajha, Munirah Altaissan, Giridhara R Babu, Zoran Gatalica, Semir Vranić

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Cancer biology & therapy · 2026
    Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Shahd HamranCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Zaineh AlnoubaniCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Aly Mostafa HassanCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Amani A Al-RajhiCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Humam Emad RajhaCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Munirah AltaissanCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Giridhara R BabuCollege of Medicine, QU Health, Qatar University, Doha, Qatar.
Zoran GatalicaPathology, Reference Medicine, Phoenix, AZ, USA.
Semir VranićCollege of Medicine, QU Health, Qatar University, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimGene fusions involving Neurotrophic Receptor Tyrosine Kinase (

methodsWe conducted a comprehensive search of databases (PubMed/MEDLINE, SCOPUS, Web of Science) and extracted data on study characteristics, molecular characteristics, and clinical outcomes. Data synthesis involved narrative and thematic analysis and study quality assessment using the Methodological Standard for Epidemiological Research (MASTER) scale.

resultsWe included 136 studies with 18,077 patients. The most common tumor categories were unclassified soft tissue sarcomas (11.09%), gynecological sarcomas (5.64%), and liposarcomas (3.37%). Most tumors were gynecologic (5.64%), followed by the limbs (1.45%). Genomic sequencing was the predominant diagnostic method used in 110 studies. Overall, 551 patients with sarcoma tested positive for

conclusionsWe confirm the rarity of

Indexed as

Biomarkers, TumorOncogene Proteins, FusionReceptor, trkAReceptor, trkCSarcomaHumansPrevalencePrognosisProtein Kinase InhibitorsBiomarkers, TumorNTRK1 protein, humanNTRK3 protein, humanOncogene Proteins, FusionProtein Kinase InhibitorsReceptor, trkAReceptor, trkCNTRK1-3 fusionsSarcomasSoft tissue tumorssystematic reviewTRK inhibitors

Identifiers

PMID41400063
PMCPMC12931729

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.